This conversation makes me nervous about policy/driven viral immune escape mutants @nataliexdean @jbloom_lab @VirusesImmunity. A controlled trial seems unlikely to determine if lower antibody titers are more likely to select for escape mutants. Does anyone know?https://twitter.com/nataliexdean/status/1345032767529168897 …
-
-
This Tweet is unavailable.
-
re: population effects of transmitted variants. Vaccine-derived immunity may be biased in IgG classes that protect lungs on progression but not select URT transmitters D1-4 (IgA, IgM).
Also <waves to Sarah> the vast complex nature of host immune bias from total past infections.
End of conversation
-
-
-
Thanks for a fascinating thread! Beyond immediate implications, though, many vaccine companies are already making strategic investments in the longer-term endemic market. With that in mind, should regulators modify the preferred profile to account for evolution going forward?
-
I think it's an interesting point for evaluating which vaccines to manufacture/buy. But in the near term, given shortages I'm guessing regulators are probably going to authorize any vaccine that demonstrates efficacy in the near term.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.